CLINICAL TRIALS PROFILE FOR ACALABRUTINIB
✉ Email this page to a colleague
All Clinical Trials for Acalabrutinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02029443 ↗ | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | Acerta Pharma BV | Phase 1/Phase 2 | 2014-01-30 | This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) |
| NCT02112526 ↗ | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | Active, not recruiting | Acerta Pharma BV | Phase 1 | 2014-08-07 | To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL). |
| NCT02157324 ↗ | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | Acerta Pharma BV | Phase 1 | 2014-08-18 | This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL) |
| NCT02180711 ↗ | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | Recruiting | Acerta Pharma, LLC | Phase 1/Phase 2 | 2015-02-01 | Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL |
| NCT02180711 ↗ | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | Recruiting | Acerta Pharma BV | Phase 1/Phase 2 | 2015-02-01 | Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL |
| NCT02180724 ↗ | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | Active, not recruiting | Acerta Pharma BV | Phase 2 | 2014-09-08 | The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM. |
| NCT02211014 ↗ | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma | Completed | Acerta Pharma, LLC | Phase 1 | 2015-02-01 | To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Acalabrutinib
Condition Name
Clinical Trial Locations for Acalabrutinib
Trials by Country
Clinical Trial Progress for Acalabrutinib
Clinical Trial Phase
Clinical Trial Sponsors for Acalabrutinib
Sponsor Name
